Antitumor Efficacy of Paclitaxel-Loaded Polylactide/Poly(ethylene glycol) Nanoparticles Combination with Exercise in Tumor-Bearing Mice
The nanoparticles (NPs) provide a promising prospect for tumor therapy, and exercise is also becoming readily and accepted as a beneficial adjunct therapy to maintain or enhance quality of life in cancer patients. We investigate the antitumor efficacy of paclitaxel (PT) loaded polylactide/poly(ethylene
glycol) NPs (PT-PLA/PEG NPs) under the exercise conditions. Results showed that within the first 7 days, the PT concentration in tumor maintained at a higher level in the PT-PLA/PEG NPs+exercise (PT-PLA/PEG NPs+EX) group as compared with the PT-PLA/PEG NPs group. All the phagocytosis rates
of macrophages were significantly decreased below the CON in exercise group. The most significant antitumor effect was observed in PT-PLA/PEG NPs+EX group, demonstrating that the PT-PLA/PEG NPs improved the concentration of PT, and exercise could further increased its therapeutic efficiency
for tumor. These researches may provide an effective means for tumor therapy.
Document Type: Research Article
Publication date: 01 June 2013
- Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content